Prostate Cancer Clinical Trial

Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer

Summary

V-0039 is a Phase 1/2 dose escalation trial of CG7870 in combination with Docetaxel in metastatic hormone-refractory patients who have not received chemotherapy.

All patients will receive docetaxel. In the dose escalation phase of the study, patients will receive treatment intravenously with CG7870 at one of up to four dose levels. In the Phase 2 portion of this study, additional patients will be added at the maximum tolerated dose that is determined in Phase 1.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically confirmed adenocarcinoma of the prostate
Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy (after discontinuation of anti-androgen therapy)
Detectable metastases by bone scan, and/or CT scan, and/or MRI, and/or CXR
ECOG performance status 0-1

Exclusion Criteria:

Transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer
History of deep vein thrombosis or pulmonary embolus
Patients taking anticoagulants (such as coumadin or Heparin). The use of aspirin while on study is acceptable.
History of a bleeding disorder or recent clinically significant bleeding
Seropositive for HIV
History of Hepatitis B, Hepatitis C, or chronic liver disease
Prior gene therapy or immunotherapy
Prior chemotherapy for prostate cancer
Radiation therapy within 4 weeks of the first treatment.
History of myocardial infarction within 6 months of the first treatment
History of cerebrovascular accident
History of previous malignancy, except for the following: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, adequately treated Stage I or II cancer currently in complete remission, or any other cancer that has been in complete remission for at least 5 years
Evidence of active prostatitis
Known hypersensitivity to docetaxel or to other drugs formulated with polysorbate 80

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

69

Study ID:

NCT00103428

Recruitment Status:

Terminated

Sponsor:

Cell Genesys

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Mary Crowley Medical Research Center
Dallas Texas, 75246, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 1

Estimated Enrollment:

69

Study ID:

NCT00103428

Recruitment Status:

Terminated

Sponsor:


Cell Genesys

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider